<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688307</url>
  </required_header>
  <id_info>
    <org_study_id>9411160001</org_study_id>
    <nct_id>NCT04688307</nct_id>
  </id_info>
  <brief_title>Cigarette Smoking in Non-alcoholic Steatohepatitis</brief_title>
  <official_title>The Effect of Cigarette Smoking Reduction on Liver Function Tests and Metabolic Profile in Subjects With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-randomized clinical trial was performed to clarify the effect of cigarette smoking&#xD;
      reduction on liver function and some anthropocentric indices in smoker patients with&#xD;
      non-alcoholic steatohepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After excluding other causes of high aminotransferase level, participants with persistent&#xD;
      elevated serum aminotransferase levels and evidence of fatty liver in ultrasonography were&#xD;
      presumed to have non-alcoholic steatohepatitis. Those with NAFLD liver fat score greater than&#xD;
      (-0.64) were enrolled. They were assigned to lifestyle modification alone or lifestyle&#xD;
      modification plus smoking reduction groups.&#xD;
&#xD;
      Liver fat content, fasting serum glucose, alanine aminotransferase, aspartate&#xD;
      aminotransferase, alkaline phosphatase, triglyceride, cholesterol, high and low-density&#xD;
      lipoprotein, homeostasis model assessment-insulin resistance(HOMA-IR), and anthropometric&#xD;
      measurements (body mass index and waist circumference) were checked at baseline and six&#xD;
      months later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fat content percent change from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Liver fat content percent changes calculated by a formula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum alanine aminotransferase level changes form baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>International unit per liter, Minimum value: 0, higher values show worse outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum aspartate aminotransferase level changes form baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>International unit per liter, Minimum value: 0, higher values show worse outcome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Lifestyle modification and smoking reduction failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is not more than 50% of the baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle modification and smoking reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is 50% of the baseline or more</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational interviewing</intervention_name>
    <description>Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight</description>
    <arm_group_label>Lifestyle modification and smoking reduction</arm_group_label>
    <arm_group_label>Lifestyle modification and smoking reduction failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Smokers with persistent elevated aminotransferase levels with the evidence of fatty liver&#xD;
        in ultrasonography, who were referred to a gastroenterology clinic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),&#xD;
&#xD;
          -  heart disease (ischemic or congestive),&#xD;
&#xD;
          -  hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease,&#xD;
             hemochromatosis, liver mass lesion),&#xD;
&#xD;
          -  renal disease (serum creatinine concentration of &gt; 1.5 mg/dl),&#xD;
&#xD;
          -  any severe systemic co-morbidities, neoplasm,&#xD;
&#xD;
          -  using any hepatotoxic medication during the past 3 months,&#xD;
&#xD;
          -  pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raika Jamali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TUMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology clinic, Sina hospital.</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sina Hospital, TUMS</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Raika Jamali, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Steatohepatitis</keyword>
  <keyword>Smoking</keyword>
  <keyword>Aminotransferase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

